baber/WOPTO huggingface dataset:
Patent NZ-536984-A (NZ)
Title: Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method
Inventor: BUNSCHOTEN EVERT JOHANNES
IPC: A61K45/06
Filed: 2003-06-06
Abstract: One aspect of the present invention is concerned with a method of controlled ovarian hyperstimulation in a mammalian female, said method comprising the co-administration to said female of - a substance having follicle stimulating hormone activity (FSH substance) in an amount effective to stimulate multiple follicular development; - gonadotropin releasing hormone (GnRH) antagonist in an amount equivalent to a daily subcutaneous dose of at least 0.5 mg ganirelix to prevent a premature LH-surge; and - a LH substance in an amount effective to prevent or suppress symptoms of luteinising hormone (LH) deficiency resulting from the administration of the GnRH antagonist; followed by administering a meiosis and luteinisation inducing substance (ML substance) in an amount effective to stimulate resumption of meiosis and luteinisation, and wherein the LH substance is not obtained from the urine of human females. Another aspect of the to invention relates to a pharmaceutical kit for use in a method of controlled hyperstimulation, which kit comprises: - at least one parenteral or oral dosage unit containing one or more FSH substances in an amount equivalent to a subcutaneous dose of 50-1500 I.U. FSH; -at least one parenteral dosage unit containing one or more GnRH antagonists in an amount equivalent to a subcutaneous dose of 0.5-25 mg ganirelix; -at least one parenteral dosage unit containing one or more LH substances in an amount equivalent to a subcutaneous dose of 50-3000 I.U. recombinant LH; wherein the LH substance is not obtained from the urine of human females.
Patent NZ-537754-A (NZ)
Title: Combination of VEGF receptor tyrosine kinase inhibitors for treatment of cancer
Inventor: WEDGE STEPHEN ROBERT
IPC: A61P35/00
Filed: 2003-08-05
Abstract: Disclosed is the use of ZD6474 or a pharmaceutically acceptable salt thereof and ZD1839 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the production of an anti-cancer effect or an anti-tumour in a human, optionally when the human is additionally being treated with ionising radiation, wherein the ZD6474 and ZD1839 may be administered simultaneously, sequentially or separately and wherein the effect of such a combination treatment is synergistic. Also disclosed is a pharmaceutical composition which comprises ZD6474 or a pharmaceutically acceptable salt thereof, and ZD1839 or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient or carrier.
Patent NZ-549344-A (NZ)
Title: A weld-free pipe clamp
Inventor: HANCOCK GEORGE REGINALD
Filed: 2006-08-22
Abstract: A pipe clamp assembly for carrying a section of pipe. The pipe clamp assembly includes at least one clamp member adapted to form a hollow section through which the pipe is adapted to extend, an attachment fitting including an elongate shaft having a first attachment means at a first end thereof for attachment with the clamp member, and a second attachment means at an opposed second end thereof, adapted to secure the fitting to a supporting structure. The at least one clamp member includes a portion that is raised from the pipe to thereby accommodate the first attachment means.
Patent NZ-551335-A (NZ)
Title: Antibodies and fragments thereof comprising an non naturally encoded amino acid coupled to a linker
Inventor: CHO HO SUNG
IPC: A61K39/395
Filed: 2005-06-17
Abstract: Disclosed is an isolated polypeptide comprising a variable chain sequence of an immunoglobulin heavy chain and a variable chain sequence of an immunoglobulin light chain, wherein the peptide sequence comprises one or more non-naturally encoded amino acids incorporated ribosomally at a selected position or at a plurality of selected positions, and wherein one or more of the non-naturally encoded amino acids is coupled to a linker having a predetermined length, such that said polypeptide binds to an antigen that is the same as an antigen to which a corresponding polypeptide lacking said non-naturally encoded amino acids binds. Further disclosed is the use of the polypeptide in the manufacture of a medicament for the treatment of a cancer.
Patent NZ-551551-A (NZ)
Title: Dental appliance and mouthguard formed of polyolefin elastomer
Inventor: ELKIN MONROE
IPC: C08L23/10
Filed: 2005-05-13
Abstract: Provided is a custom-fit dental appliance comprising one or more channels and an upstanding wall extending from said one or more channels being formed of a semi-crystalline polyolefin polymer, or a crystallisable polymer blend wherein said dental appliance securely fits to teeth; wherein the crystallisable semi-crystalline is polyolefin propylene ethylene copolymer comprising about 8% to about 25% by weight of ethylene-derived units and about 75% to about 90% by weight of propylene, wherein said semi-crystalline propylene ethylene copolymer is formed by copolymerizing propylene and ethylene using a chiral metallocene catalyst system, said semi-crystalline propylene-ethylene copolymer having crystallinity from about 2% to about 65% from polypropylene sequence and said crystallisable polymer blend is formed by blending at least a first polymer component and a second polymer component, the blend comprising: from about 2% to about 95% by weight of the first polymer component, the first polymer component comprising isotactic polypropylene and having a melting point greater than about 110° C, and copolymerizing propylene and ethylene using a chiral metallocene catalyst system, the copolymer having crystallinity from about 2% to about 65% from isotactic polypropylene sequences, a propylene content of from about 75% to about 90% by weight.
Patent NZ-564311-A (NZ)
Title: Frequency segmentation to obtain bands for efficient coding of digital media
Inventor: MEHROTRA SANJEEV
IPC: G10K11/16
Filed: 2006-07-14
Abstract: A method for an audio processing device to encode audio is provided. The method includes: transforming an input block of an audio signal into spectral data, where the spectral data has a baseband portion and an extended band portion; coding the baseband portion of the spectral data into an output bitstream; in the extended band portion of the spectral data, determining characteristics of spectral data; altering an initial configuration by which the extended band portion of the spectral data is segmented into a number of sub-bands based on the determined characteristics; and coding the altered configuration of sub-bands including data indicating individual sub-bands in the extended band altered from the initial configuration. A method for an audio processing device to decode a bitstream representing an audio signal is also provided. The method includes: decoding an encoded baseband from the bitstream; and decoding an encoded extended band from the bitstream. The decoding includes: receiving data including a minimum ratio sub-band size and an altered configuration of sizes of a number of variable size sub-bands; determining a smallest sub-band size in the altered configuration by dividing the smallest sub-band size in the default configuration by the minimum ratio sub-band size; and determining an actual sub-band multiplier by adding an expected sub-band multiplier to a coded difference value.
Patent NZ-574987-A (NZ)
Title: Electrically controlled lock assembly comprising electrical actuator that includes solenoid with a plunger
Inventor: BLANCH DAVID
IPC: E05B47/00
Filed: 2007-07-30
Abstract: An electrically controlled lock assembly (1) is disclosed. The assembly includes a housing (8) and a keeper (6) mounted on the housing (8) for relative movement between an open and closed position. The lock assembly (1) also includes a locking means including a detent that when retained in an active position stops the keeper (6) from moving relative to the housing (8). The lock assembly (1) also includes an electrical actuator in the form of solenoid with an adjustable plunger that can cause retaining means to adopt a locked or released condition when the solenoid is activated.
Patent NZ-581096-A (NZ)
Title: Banded papers and smoking articles with a layer comprising a propylene glycol anti-wrinkling agent
Inventor: LI PING
IPC: A24D1/02
Filed: 2008-05-30
Abstract: Disclosed are banded wrappers for use in cigarette manufacturing and smoking articles having an ignition propensity value less than about 25 and a self-extinction value less than about 50, comprising: a quantity of tobacco; a wrapper paper surrounding the quantity of tobacco and defining a tobacco rod having a mouth end; a filter attached to the mouth end of the tobacco rod; and add-on material applied to the wrapper paper in a pattern, the add-on material having been applied as an aqueous starch solution including starch and propylene glycol or glycerine.
Patent NZ-584663-A (NZ)
Title: Use of immunomodulatory amino-dione derivatives for treating leukemia
Inventor: ZELDIS JEROME B
IPC: A61K31/4035
Filed: 2003-05-16
Abstract: Disclosed herein is a use of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione, 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, in the manufacture of a pharmaceutical composition for treating leukemia, wherein the leukemia may be chronic lymphocytic leukemia, chronic myelocytic leukemia, acute lymphoblastic leukemia, acute myelogenous leukemia or acute myeloblastic leukemia.
Patent NZ-591103-A (NZ)
Title: Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides
Inventor: PIER GERALD B
IPC: C07K14/31
Filed: 2009-07-21
Abstract: Disclosed are compounds of Formula III and IV, which are activated ester precursors to oligosaccharide-carrier linkers of Formula VIIIa and VIIIb. The oligosaccharide-linker-carrier compounds disclosed are useful for antigenic compositions such as vaccines and are able to stimulate an immune response to microbial polysaccharide antigens. The stimulated immune response is useful in the treatment or prevention of various infections such as Staphylococcal infections.
Patent NZ-591753-A (NZ)
Title: Lighting apparatus which has a light source releasably secured to a mounting structure
Inventor: BOYER JOHN D
IPC: F21V15/01
Filed: 2009-09-25
Abstract: Disclosed is a lighting apparatus (10) with a lighting component which is designed to be releasably mounted to a mounting structure (14) to facilitate simple installation and maintenance. The lighting apparatus includes a lighting component which contains a light source, a plate (66), and a frame. The lighting component has at least one engagement flange (62) with a window (76) designed to engage with a tab (77). The lighting apparatus further has a mounting structure which the lighting component can be releasably attached to by engaging one or more tabs on the mounting structure with the tab engaging windows of the lighting structure.
Patent NZ-595244-A (NZ)
Title: Handling a scheduling request trigger
Inventor: OSTERGAARD JESSICA
IPC: H04W72/12
Filed: 2010-01-25
Abstract: 595244 Disclosed is a user equipment (120) for handling a scheduling request trigger in a communication system. The user equipment (120) has a buffer (120) configured to receive data to be transmitted to a base station. The user equipment (120) is configured to generate a buffer status report trigger, the generation of which is triggered by the arrived data. The user equipment also includes a generating unit (920) configured to generate a scheduling request trigger which is pending until it is cancelled by a cancelling unit (930) and is triggered by the generation of the buffer status report trigger. The user equipment (120) also includes means for sending (940) a scheduling request if and only if the buffer (900) comprises data that has not yet been accounted for in a buffer status report.
Patent NZ-596586-A (NZ)
Title: Micro organism test apparatus with multiple puncturable chambers
Inventor: SHARPIN ROSEMARY KATHERINE CAMERON
IPC: B65D25/08
Filed: 2005-06-23
Abstract: A container 70 for testing micro-organisms, the container 70 having a substantially rigid transparent chamber 85 configured to allow a light beam to pass into the container 70 and be measured by one or more light detectors. The container 70 has a base 73 and a removable cap 71, a second chamber and a barrier 95 separating the second chamber from the transparent chamber 85. The second chamber contains a growth promoter and/or a dye adapted to assist in detecting a presence or absence of micro-organisms and a barrier puncturing mechanism 83 for releasing the growth promoter and/or the dye into the transparent chamber 85. The container 70 also includes a third chamber and a barrier 96 separating the third chamber from the transparent chamber. The third chamber contains a sanitizer, and a barrier puncturing mechanism for releasing the sanitizer into the container 70.
Patent NZ-597449-A (NZ)
Title: A signal generator and a method of generating a Composite Binary Offset Carrier signal, the Composite Binary Offset Carrier signal and a navigation signal thereof with a receiver to process the navigation signal
Inventor: PRATT ANTHONY R
IPC: H04J13/10
Filed: 2007-06-20
Abstract: A signal generator and a method of generating a Composite Binary Offset Carrier signal (CBOC) or spreading modulation signal from first and second Binary Offset Carrier (BOC) signals are disclosed. The signal has a predetermined power spectral density comprising at least reduced cross spectral terms of the power spectral densities of the first and second BOC signal averaged over at least two predetermined time intervals. The signal generator comprises means to arrange for the states of the first and second BOC signals over a subsequent predetermined time interval of the at least two predetermined time intervals to be complementary to the states of the first and second BOC signals over a current predetermined time interval of the at least two predetermined time intervals. Further disclosed are the resulting Composite Binary Offset Carrier signal having a predetermined power spectral density and a navigation signal comprising a combination of a carrier, a ranging code and the CBOC signal. The CBOC comprises at least reduced cross spectral terms of the power spectral densities of first and second BOC signals averaged over at least two predetermined time intervals. The phase states of the first and second BOC signals over a subsequent predetermined time interval of the at least two predetermined time intervals are complementary to the phase states of the first and second BOC signals over a current predetermined time interval of the at least two predetermined time intervals. Further disclosed is a receiver comprising a means adapted to process the above described navigation signal. The receiver comprises an antenna for receiving the navigation signal; an RF processor for amplifying, filtering and frequency changing the received navigation signal, and producing digitised received signal samples therefrom.
Patent NZ-598778-A (NZ)
Title: Combination therapy with SGLT-2 inhibitors and their pharmaceutical compositions
Inventor: MANUCHEHRI ALIREZA
IPC: A61K31/341
Filed: 2007-11-08
Abstract: Disclosed is a pharmaceutical composition comprised of one SGLT-2 inhibitor compound in combination with a second therapeutic agent which is suitable for the treatment of one or more metabolic disorders, wherein i) said one SGLT-2 inhibitor compound is the glucopyranosyl-substituted benzene derivative: l-chloro-4-(,8-D-glucopyranos-l-yl)-2-[ 4-((S)-tetrahydrofuran-3-yloxy)benzyl]- benzene; and ii) said second therapeutic agent which is suitable for the treatment of one or more metabolic disorders is metformin; and wherein the SGLT -2 inhibitor compound and the second therapeutic agent are present in a single dosage form, and wherein the composition is adapted to provide a dosage of the SGLT-2 inhibitor compound which is in the range from 10 to 50 mg per day and a dosage of the second therapeutic agent which is in the range from 500 to 1000 mg per day.
Patent NZ-601526-A (NZ)
Title: Inhibitors of diacylglycerol acyl transferase
Inventor: JADHAV RAVINDRA DNYANDEV
IPC: C07D417/12
Filed: 2010-12-30
Abstract: Provided herein is a heterocyclic compound of formula 1, wherein the variables are defined in the specification, in all their stereoisomeric and tautomeric forms; and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutically acceptable polymorphs. Also provided are processes for the manufacture of the heterocyclic compounds and to pharmaceutical compositions containing them. The said compounds and their pharmaceutical compositions are useful in the prevention and treatment of diseases or disorders mediated by diacylglycerol acyltransferase (DGAT), particularly DGAT1. Further provided is method of treatment of such diseases or disorders by administering a therapeutically effective amount of said compounds or their pharmaceutical compositions, to a mammal in need thereof. In one embodiment the compound is methyl 3-methyl-2-(5-(4-(3-(2-(trifluoromethyl)phenyl)ureido)phenyl)isoindolin-2-yllbutanoate.
Patent NZ-602057-A (NZ)
Title: Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof
Inventor: NARAIN NIVEN RAJIN
IPC: A61P35/00
Filed: 2011-03-11
Abstract: Disclosed is a therapeutic formulation suitable for intravenous administration to a subject comprising: an aqueous solution; a hydrophobic active agent a dispersion stabilizing agent; and an opsonization reducer; wherein the hydrophobic active agent is Coenzyme Q10 (CoQ10); wherein the dispersion stabilizing agent is Dimyristoylphosphatidyl choline (DMPC); and wherein the hydrophobic active agent is dispersed into a colloidal nano-dispersion of particles having a mean size of between about 10-nm and about 100-nm.
Patent NZ-603262-A (NZ)
Title: Token with electronic device
Inventor: CHAPET PIERRE
IPC: A44C21/00
Filed: 2007-05-25
Abstract: 603262 A casino chip or gaming token which has an insert. The insert includes a one-piece rigid plate with an electrically insulating first face and second face and a contactless identification device attached to the first face of the one-piece rigid plate. The insert also has two protection layers obtained by injection of material, covering the first and second faces of the one-piece rigid plate. The one-piece rigid plate has a through-hole enabling the protection layers to be fastened together through rigid plate by the formation of a bridge of material passing through the through-hole and obtained by the injection of material.
Patent NZ-603800-A (NZ)
Title: Substituted 5-fluoro-1h-pyrazolopyridines and use thereof
Inventor: GRIEBENOW NILS
IPC: C07D471/04
Filed: 2011-05-24
Abstract: Disclosed herein are substituted 5-fluoro-1H-pyrazolopyridines of general formula (I), wherein the substituents are as defined within the specification, processes for their preparation, compositions comprising said compounds and uses thereof. Said compounds are useful for the treatment and/or prophylaxis of heart failure, angina pectoris, hypertension, pulmonary hypertension, ischaemias, vascular disorders, kidney failure, thromboembolic disorders, fibrotic disorders and arteriosclerosis. Particularly preferred compounds include: methyl { 4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl} carbamate; methyl { 4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl} methylcarbamate; methyl { 4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl ]pyrimidin-5-yl} (2,2,2-trifluoroethyl)carbamate; methyl { 4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl} carbamate hydrochloride; methyl { 4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl} carbamate maleate; methyl { 4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl} carbamate nitrate.
Patent NZ-603854-A (NZ)
Title: West nile virus vaccine
Inventor: HENNESSY KRISTINA J
IPC: A61P31/12
Filed: 2009-08-31
Abstract: Disclosed is an immunogenic composition comprising one or more strains of killed or inactivated West Nile Virus or any antigen thereof, wherein said West Nile Virus is a North American Dominant West Nile Strain or Isolate, and wherein the North American Dominant West Nile Strain or Isolate has at least one nucleotide change resulting in an amino acid change from the reference strain NY99, wherein the nucleotide change results in an amino acid change from valine to alanine at position 159 in the critical envelope protein.
Patent NZ-608900-A (NZ)
Title: A container assembly and a cap assembly for a container
Inventor: MEL BOTHA
IPC: B65D47/06
Filed: 2013-04-02
Abstract: A container assembly 10 comprising a container 12 having an opening, a cap 20 having an aperture and being adapted to removably engage the container 12 for covering the opening, an integrally formed spigot 24 adapted to releasably engage delivery means extended into the aperture of the cap 20 and to facilitate drawing of the contents of the container 12 from the container 12, and a tamper resistant sealing means which is a removable plug which seals the spigot 32 from the surrounding environment. The removable plug is an externally threaded cylindrical plug for engaging the aperture within the cap 20. The integrally formed spigot 24 is located towards the centre portion of the aperture formed in the cap 20, and there is provided at least one breather valve which is integrally formed or removably mounted within the aperture formed in the cap 20.
Patent NZ-609826-A (NZ)
Title: Active enantiomer of dodecyl 2-(n,n-dimethylamino)-propionate
Inventor: MARTIN RICHARD
IPC: C07C229/12
Filed: 2011-11-30
Abstract: Provided are purified forms of 2R-dodecyl 2-(N,N-dimethylamino)-propionate (R-DDAIP) and 2S-dodecyl 2-(N,N-dimethylamino)-propionate (S-DDAIP). Further provided is the use of R-DDAIP for facilitating the transport of an active pharmaceutical, such as lansoprazole, across a biological tissue or membrane to increase its absorption.
Patent NZ-611902-A (NZ)
Title: Culture method to obtain and maintain a pure or enriched population of mammalian neural stem cells and/or neural progenitor cells that are prone to differentiate into oligodendrocyte-lineage cells in vitro
Inventor: KIDO TSUNEO
IPC: C12N5/0797
Filed: 2012-01-12
Abstract: Disclosed is an enriched population of expanded human neural cells wherein the cells are progenitor cells or stem cells, wherein the cells have been cultured under conditions effective to enrich for the expanded human neural cells, wherein the conditions effective to enrich for expanded neural cells comprise a cell culture medium comprising at least one growth supplement in an effective amount, at least two growth factors, and at least one survival factor; wherein the at least one growth supplement is 1-thioglycerol and the effective amount of the growth supplement in the cell culture medium is at least 10 μM of 1-thioglycerol; wherein the cells maintain their capability to differentiate into neurons, astrocytes, and oligodendrocytes; wherein the cells maintain their ability to differentiate into oligodendrocyte lineage cells efficiently throughout subsequent passages of the culture; and wherein the population of cells express at least the cell surface antigens CD133, CD140a, A2B5 and PSA-NCAM. Also disclosed is the use of said enriched population of cells in the preparation of a medicament for the treatment of demyelinating disease or neurodegenerative disease.